Current and future advances in practice: IgG4-related disease

Area of Science:

• Immunology
• Rheumatology
• Pathology

Background:

• Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory condition with increasing recognition across diverse populations.
• Pathogenesis involves B and T cells, making them targets for novel therapies.
• Current diagnostic methods rely on clinicopathological correlation due to a lack of specific biomarkers.

Purpose of the Study:

• To review the current understanding of IgG4-related disease (IgG4-RD) etiology and pathogenesis.
• To highlight the diagnostic challenges and limitations of current treatments.
• To emphasize the need for glucocorticoid-sparing agents and evaluate emerging therapeutic strategies.

Main Methods:

• Literature review of existing studies on IgG4-related disease (IgG4-RD).
• Analysis of the roles of B and T cells in IgG4-RD pathogenesis.
• Evaluation of current and potential therapeutic interventions, including B cell-targeted therapies.

Main Results:

• IgG4-RD is associated with significant mortality and risk of irreversible organ damage.
• Glucocorticoids are effective but limited by toxicity.
• B cell-targeted therapies like rituximab show promise, but require further randomized clinical trials for efficacy validation.

Conclusions:

• Effective management of IgG4-RD necessitates understanding its complex etiology and pathogenesis.
• There is a critical need for glucocorticoid-sparing agents and rigorous evaluation of novel immunosuppressive strategies.
• Long-term monitoring and tailored immunosuppression are crucial for preventing organ damage in IgG4-RD patients.